Effects of circulating endogenous catecholamines on plasma glucose, potassium and magnesium.
1. To examine the metabolic effects of increases in circulating endogenous plasma catecholamines, we measured plasma glucose, potassium and magnesium in 14 patients undergoing elective coronary artery bypass grafting. The patients were randomized into two groups and received either sodium nitroprusside (a direct-acting vasodilator) or trimetaphan camsylate (a ganglion-blocking agent) for routine control of blood pressure during the operation. 2. There were significant differences between the two groups in the levels of all three metabolic variables studied. Plasma glucose levels rose in both groups, but were significantly higher in the sodium nitroprusside group [peak levels 9.14 (SEM 0.72)mmol/l compared with 6.71 (0.88) mmol/l, P less than 0.001, analysis of variance]. The cardioplegia solution caused a large increase in plasma magnesium in both groups but in the sodium nitroprusside group the level rose higher [to 1.59 (0.12)mmol/l compared with 1.34 (0.06)mmol/l] and fell faster (P less than 0.05, analysis of variance). In the group receiving sodium nitroprusside, plasma potassium fell, by a mean of 0.34mmol/l, as plasma catecholamine levels rose; no such fall was seen in the group receiving trimetaphan camsylate (P less than 0.05, analysis of variance). 3. It is concluded that the sympathoadrenal system is important in causing metabolic changes during cardiopulmonary bypass and may be relevant in other conditions such as acute myocardial infarction.
Corr
L A
LA
Department of Clinical Pharmacology, Hammersmith Hospital, London.
Grounds
R M
RM
Beacham
J L
JL
Whitwam
J G
JG
Brown
M J
MJ
D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D001026:Coronary Artery Bypass; D004837:Epinephrine / Q000502:physiology*; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D008274:Magnesium / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside / Q000627:therapeutic use; D011188:Potassium / Q000097:blood*; D011897:Random Allocation; D014294:Trimethaphan / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D001786:Blood Glucose; D014665:Vasodilator Agents; D009599:Nitroprusside; D014294:Trimethaphan; C017774:trimethaphan camsylate; D008274:Magnesium; D011188:Potassium; D004837:Epinephrine